雑誌文献を検索します。書籍を検索する際には「書籍検索」を選択してください。

検索

書誌情報 詳細検索 by 医中誌

Japanese

Therapeutic Strategies for The Polyglutamine Diseases Yoshitaka Nagai 1 , H. Akiko Popiel 1 , Nobuhiro Fujikake 1 , Tatsushi Toda 1 1Division of Clinical Genetics, Department of Medical Genetics, Osaka University Graduate School of Medicine Keyword: polyglutamine diseases , Huntington disease , spinocerebellar ataxia , neurodegenerative diseases , therapy pp.393-404
Published Date 2007/4/1
DOI https://doi.org/10.11477/mf.1416100061
  • Abstract
  • Look Inside
  • Reference

Abstract

 The polyglutamine diseases are a group of nine inherited neurodegenerative diseases including Huntington disease, spinocerebellar ataxia type 1,2,3,6,7 and 17, dentatorubral pallidoluysian atrophy, and spinobulbar muscular atrophy,which are caused by an abnormal expansion of the CAG repeat encoding a polyglutamine stretch in each unrelated disease-causing gene. In the pathogenesis of the polyglutamine diseases, expansion of the polyglutamine stretch causes misfolding and conformational alterations of the disease-causing proteins, leading to pathogenic protein-protein interactions including aggregate formation, and subsequently resulting in their deposition as inclusion bodies in affected neurons. Expression of these expanded polyglutamine proteins has been reported to impair protein degradation, transcriptional regulation, axonal transport, mitochondrial function, etc., which eventually result in neurodegeneration. Currently, a wide variety of research towards establishing therapies targeting each step in the pathogenesis of the polyglutamine diseases is in progress, which includes suppressing mutant gene expression by RNAi, inhibiting protein misfolding/aggregation, promoting protein degradation, activating transcription, activating mitochondrial function, inhibiting neuronal cell death, and neuroprotection by neurotrophic factors. Standardized validation of these preclinical studies and development of sensitive biomarkers for evaluation of therapeutic efficacy in clinical trials will be necessary for development of drugs for the polyglutamine diseases.


Copyright © 2007, Igaku-Shoin Ltd. All rights reserved.

基本情報

電子版ISSN 1344-8129 印刷版ISSN 1881-6096 医学書院

関連文献

もっと見る

文献を共有